New evidence pyramid

M Hassan Murad, Noor Asi, Mouaz Alsawas, Fares Alahdab

Abstract

A pyramid has expressed the idea of hierarchy of medical evidence for so long, that not all evidence is the same. Systematic reviews and meta-analyses have been placed at the top of this pyramid for several good reasons. However, there are several counterarguments to this placement. We suggest another way of looking at the evidence-based medicine pyramid and explain how systematic reviews and meta-analyses are tools for consuming evidence—that is, appraising, synthesising and applying evidence.

The first and earliest principle of evidence-based medicine indicated that a hierarchy of evidence exists. Not all evidence is the same. This principle became well known in the early 1990s as practising physicians learnt basic clinical epidemiology skills and started to appraise and apply evidence to their practice. Since evidence was described as a hierarchy, a compelling rationale for a pyramid was made. Evidence-based healthcare practitioners became familiar with this pyramid when reading the literature, applying evidence or teaching students.

Various versions of the evidence pyramid have been described, but all of them focused on showing weaker study designs in the bottom (basic science and case series), followed by case-control and cohort studies in the middle, then randomised controlled trials (RCTs), and at the very top, systematic reviews and meta-analysis. This description is intuitive and likely correct in many instances. The placement of systematic reviews at the top had undergone several alterations in interpretations, but was still thought of as an item in a hierarchy. Most versions of the pyramid clearly represented a hierarchy of internal validity (risk of bias). Some versions incorporated external validity (applicability) in the pyramid by either placing N-1 trials above RCTs (because their results are most applicable to individual patients) or by separating internal and external validity.

Another version (the 6S pyramid) was also developed to describe the sources of evidence that can be used by evidence-based medicine (EBM) practitioners for answering foreground questions, showing a hierarchy ranging from studies, synopses, synthesis, synopses of synthesis, summaries and systems. This hierarchy may imply some sort of increasing validity and applicability although its main purpose is to emphasise that the lower sources of evidence in the hierarchy are least preferred in practice because they require more expertise and time to identify, appraise and apply.
The traditional pyramid was deemed too simplistic at times, thus the importance of leaving room for argument and counterargument for the methodological merit of different designs has been emphasised. Other barriers challenged the placement of systematic reviews and meta-analyses at the top of the pyramid. For instance, heterogeneity (clinical, methodological or statistical) is an inherent limitation of meta-analyses that can be minimised or explained but never eliminated. The methodological intricacies and dilemmas of systematic reviews could potentially result in uncertainty and error. One evaluation of 163 meta-analyses demonstrated that the estimation of treatment outcomes differed substantially depending on the analytical strategy being used. Therefore, we suggest, in this perspective, two visual modifications to the pyramid to illustrate two contemporary methodological principles (figure 1). We provide the rationale and an example for each modification.

**Rationale for modification 1**

In the early 2000s, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group developed a framework in which the certainty in evidence was based on numerous factors and not solely on study design which challenges the pyramid concept. Study design alone appears to be insufficient on its own as a surrogate for risk of bias. Certain methodological limitations of a study, imprecision, inconsistency and indirectness, were factors independent from study design and can affect the quality of evidence derived from any study design. For example, a meta-analysis of RCTs evaluating intensive glycaemic control in non-critically ill hospitalised patients showed a non-significant reduction in mortality (relative risk of 0.95 [95% CI 0.72 to 1.25]). Allocation concealment and blinding were not adequate in most trials. The quality of this evidence is rated down due to the methodological limitations of the studies, imprecision, inconsistency and indirectness, were factors independent from study design and can affect the quality of evidence. Hence, despite the fact of having five RCTs, such evidence should not be rated high in any pyramid. The quality of evidence can also be rated up. For example, we are quite certain about the benefits of hip replacement in a patient with disabling hip osteoarthritis. Although not tested in RCTs, the
The mortality rate was significantly lower in patients who underwent endovascular repair, followed by open repair and non-operative management (9%, 19% and 46%, respectively, p<0.01). Clearly, this meta-analysis should not be on top of the pyramid similar to a meta-analysis of RCTs. After all, the evidence remains consistent of non-randomised studies and likely subject to numerous confounders.

Therefore, the second modification to the pyramid is to remove systematic reviews from the top of the pyramid and use them as a lens through which other types of studies should be seen (ie, appraised and applied). The systematic review (the process of selecting the studies) and meta-analysis (the statistical aggregation that produces a single effect size) are tools to consume and apply the evidence by stakeholders.

Implications and limitations

Changing how systematic reviews and meta-analyses are perceived by stakeholders (patients, clinicians and stakeholders) has important implications. For example, the American Heart Association considers evidence derived from meta-analyses to have a level ‘A’ (ie, warrants the most confidence). Re-evaluation of evidence using GRADE shows that level ‘A’ evidence could have been high, moderate, low or of very low quality. The quality of evidence drives the strength of recommendation, which is one of the last translational steps of research, most proximal to patient care.

One of the limitations of all ‘pyramids’ and depictions of evidence hierarchy relates to the underpinning of such schemas. The construct of internal validity may have varying definitions, or be understood differently among evidence consumers. A limitation of considering systematic review and meta-analyses as tools to consume evidence may undermine their role in new discovery (eg, identifying a new side effect that was not demonstrated in individual studies).

This pyramid can be also used as a teaching tool. EBM teachers can compare it to the existing pyramids to explain how certainty in the evidence (also called quality of evidence) is evaluated. It can be used to teach how evidence-based practitioners can appraise and apply systematic reviews in practice, and to demonstrate the evolution in EBM thinking and the modern understanding of certainty in evidence.

Contributors

MHM conceived the idea and drafted the manuscript. FA helped draft the manuscript and designed the new pyramid. MA and NA helped draft the manuscript.

Competing interests

None declared.

Provenance and peer review

Not commissioned; externally peer reviewed.

References